<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">477125697</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180405111648.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170330e19970601xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1023/A:1012190120061</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1023/A:1012190120061</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="4">
   <subfield code="a">The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Xanthe Lam, Thomas Patapoff, Tue Nguyen]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Purpose. The goal of this study was to investigate the conformational change and aggregation of recombinant human interferon-gamma (rhIFN-γ) as a result of interaction between benzyl alcohol and the protein. The effects of buffer concentration, buffer species, ionic strength, rhIFN-γ and benzyl alcohol concentrations on the dynamics of the interaction in liquid formulations were also examined. Methods. The effect of benzyl alcohol on the secondary and tertiary structure of rhIFN-γ in succinate and acetate buffers was studied using far-UV and near-UV circular dichroism spectrophotometry, respectively. Dynamic light scattering was employed to detect aggregate formation due to the interaction of benzyl alcohol with rhIFN-γ. Results. The addition of benzyl alcohol at 0.9% (w/v) in various liquid rhIFN-γ formulations induced changes in circular dichroism (CD) spectra of the protein in the near-UV region, while the CD spectra in the far-UV region remained unaltered. There were gradual decreases in ellipticity with time throughout the near-UV CD spectra. The decreases in near-UV ellipticity induced by benzyl alcohol were accompanied by the formation of high molecular weight aggregates as measured by dynamic light scattering. Loss in near-UV ellipticity was accelerated at lower protein concentration and by increasing buffer or benzyl alcohol concentration. It was also faster in succinate than in acetate buffer. Formulation ionic strength did not affect the CD spectral changes in both the near- and far-UV regions. Conclusions. Interaction between benzyl alcohol and rhIFN-γ is formulation dependent. Protein concentration, buffer species, buffer concentration, and preservative concentration play a significant role in determining the extent of the interaction and consequently the stability of the product.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Plenum Publishing Corporation, 1997</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">recombinant human interferon-γ (rhIFN-γ)</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">benzyl alcohol</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">circular dichroism</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">ellipticity</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">dynamic light scattering</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">aggregation</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Lam</subfield>
   <subfield code="D">Xanthe</subfield>
   <subfield code="u">Department of Pharmaceutical Research and Development, Genentech, Inc., 460 Pt. San Bruno Blvd., South San Francisco, California, 94080</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Patapoff</subfield>
   <subfield code="D">Thomas</subfield>
   <subfield code="u">Department of Pharmaceutical Research and Development, Genentech, Inc., 460 Pt. San Bruno Blvd., South San Francisco, California, 94080</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Nguyen</subfield>
   <subfield code="D">Tue</subfield>
   <subfield code="u">Department of Pharmaceutical Research and Development, Genentech, Inc., 460 Pt. San Bruno Blvd., South San Francisco, California, 94080</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Pharmaceutical Research</subfield>
   <subfield code="d">Kluwer Academic Publishers-Plenum Publishers</subfield>
   <subfield code="g">14/6(1997-06-01), 725-729</subfield>
   <subfield code="x">0724-8741</subfield>
   <subfield code="q">14:6&lt;725</subfield>
   <subfield code="1">1997</subfield>
   <subfield code="2">14</subfield>
   <subfield code="o">11095</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1023/A:1012190120061</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1023/A:1012190120061</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Lam</subfield>
   <subfield code="D">Xanthe</subfield>
   <subfield code="u">Department of Pharmaceutical Research and Development, Genentech, Inc., 460 Pt. San Bruno Blvd., South San Francisco, California, 94080</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Patapoff</subfield>
   <subfield code="D">Thomas</subfield>
   <subfield code="u">Department of Pharmaceutical Research and Development, Genentech, Inc., 460 Pt. San Bruno Blvd., South San Francisco, California, 94080</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Nguyen</subfield>
   <subfield code="D">Tue</subfield>
   <subfield code="u">Department of Pharmaceutical Research and Development, Genentech, Inc., 460 Pt. San Bruno Blvd., South San Francisco, California, 94080</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Pharmaceutical Research</subfield>
   <subfield code="d">Kluwer Academic Publishers-Plenum Publishers</subfield>
   <subfield code="g">14/6(1997-06-01), 725-729</subfield>
   <subfield code="x">0724-8741</subfield>
   <subfield code="q">14:6&lt;725</subfield>
   <subfield code="1">1997</subfield>
   <subfield code="2">14</subfield>
   <subfield code="o">11095</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
